Toggle menu

TICH 2

Start date:
October 2013
End date:
February 2018
Co-ordinated by:
University of Nottingham
Main trial site:
http://tich-2.org

Tranexamic Acid for Hyperacute Primary IntraCerebral Haemorrhage

Aim

To assess whether tranexamic acid is safe and reduces death and dependency after hyperacute (within 8 hours of onset) spontaneous intracerebral haemorrhage.

Trial Design

A phase III prospective pragmatic double blind randomised placebo controlled trial

Chief Investigator

Dr Nikola Sprigg (Medical expert) Clinical Associate Professor, University of Nottingham

Principal Investigator

Professor Rustam Al-Shahi Salman, Professor of clinical neurology, University of Edinburgh & NHS Lothian

Local lead in ED

Dr Matt Reed is the local contact for recruitment of ED patients into the study.

Research Team

  • EMERGE Research team
  • Stroke Research Group

Eligibility criteria (summary)

Patients who present to the ED within 8 hours of acute spontaneous intracerebral haemorrhagic stroke.

Further information

For more information please refer to main trial website

Research Team

Dr Matt Reed

Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Bernadette Gallagher

Senior Research Nurse

More EMERGE Trials

MAPP2

The Markers and Paracetamol Poisoning Study 2

The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.

Read more

The POP Trial

A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)